Acceleration of cutaneous T-cell lymphoma following dupilumab administration
Kristen Russomanno, Cynthia Marie Carver DeKlotz
Abstract
Recent advances in the treatment of moderate-to-severe atopic dermatitis have led to increased use of dupilumab, which is a human monoclonal antibody that binds to the interleukin (IL) 4-receptor-alpha subunit. Reports have recently been published describing worsening of disease in patients with cutaneous T-cell lymphoma (CTCL) treated with dupilumab either inadvertently or as off-label use. We present an additional case of worsening CTCL following treatment with dupilumab for presumed atopic dermatitis.
Topics & Concepts
DupilumabMedicineAtopic dermatitisDermatologyMonoclonal antibodyLymphomaMonoclonalImmunologyDiseaseAntibodyInternal medicineCutaneous lymphoproliferative disorders researchNail Diseases and TreatmentsFungal Infections and Studies